Given that AML cells that harbor FLT3 mutations co-express FLT3wt [27], FL-dependent resistance to FLT3 inhibitors is considered one of the obstacles to treatment of AML patients with FLT3wt/mut. Here, FLT3LG is linked to acute myeloid leukemia.